299 related articles for article (PubMed ID: 36831561)
1. The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies.
Zhu Y; Wang Z; Li Y; Peng H; Liu J; Zhang J; Xiao X
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831561
[TBL] [Abstract][Full Text] [Related]
2. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis.
Huang YH; Cai K; Xu PP; Wang L; Huang CX; Fang Y; Cheng S; Sun XJ; Liu F; Huang JY; Ji MM; Zhao WL
Signal Transduct Target Ther; 2021 Jan; 6(1):10. PubMed ID: 33431788
[TBL] [Abstract][Full Text] [Related]
3. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma.
Wei W; Song Z; Chiba M; Wu W; Jeong S; Zhang JP; Kadin ME; Nakagawa M; Yang Y
Leukemia; 2023 Feb; 37(2):396-407. PubMed ID: 36456744
[TBL] [Abstract][Full Text] [Related]
4. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Drug-like EP300/CREBBP Acetyltransferase Inhibitors.
Crawford MC; Tripu DR; Barritt SA; Jing Y; Gallimore D; Kales SC; Bhanu NV; Xiong Y; Fang Y; Butler KAT; LeClair CA; Coussens NP; Simeonov A; Garcia BA; Dibble CC; Meier JL
ACS Chem Biol; 2023 Oct; 18(10):2249-2258. PubMed ID: 37737090
[TBL] [Abstract][Full Text] [Related]
6. The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.
Wu W; Jiang Y; Xing D; Zhai Y; Sun H; He X; Luo K; Xu P; Pan F; Dong G; Ren G; Zhao Z
Cell Death Discov; 2024 May; 10(1):206. PubMed ID: 38693103
[TBL] [Abstract][Full Text] [Related]
7. CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; Graña-Castro O; Pisano DG; Barrero MJ
Epigenetics Chromatin; 2018 Jun; 11(1):30. PubMed ID: 29884215
[TBL] [Abstract][Full Text] [Related]
8. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Qian M; Zhang H; Kham SK; Liu S; Jiang C; Zhao X; Lu Y; Goodings C; Lin TN; Zhang R; Moriyama T; Yin Z; Li Z; Quah TC; Ariffin H; Tan AM; Shen S; Bhojwani D; Hu S; Chen S; Zheng H; Pui CH; Yeoh AE; Yang JJ
Genome Res; 2017 Feb; 27(2):185-195. PubMed ID: 27903646
[TBL] [Abstract][Full Text] [Related]
9. CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Garcia-Carpizo V; Ruiz-Llorente S; Sarmentero J; González-Corpas A; Barrero MJ
Mol Cancer Res; 2019 Mar; 17(3):720-730. PubMed ID: 30606771
[TBL] [Abstract][Full Text] [Related]
10. Analysis of genetic stability at the EP300 and CREBBP loci in a panel of cancer cell lines.
Tillinghast GW; Partee J; Albert P; Kelley JM; Burtow KH; Kelly K
Genes Chromosomes Cancer; 2003 Jun; 37(2):121-31. PubMed ID: 12696060
[TBL] [Abstract][Full Text] [Related]
11. CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
Veazey KJ; Cheng D; Lin K; Villarreal OD; Gao G; Perez-Oquendo M; Van HT; Stratton SA; Green M; Xu H; Lu Y; Bedford MT; Santos MA
Leukemia; 2020 Dec; 34(12):3269-3285. PubMed ID: 32576962
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function.
Kumar M; Molkentine D; Molkentine J; Bridges K; Xie T; Yang L; Hefner A; Gao M; Bahri R; Dhawan A; Frederick MJ; Seth S; Abdelhakiem M; Beadle BM; Johnson F; Wang J; Shen L; Heffernan T; Sheth A; Ferris RL; Myers JN; Pickering CR; Skinner HD
Nat Commun; 2021 Nov; 12(1):6340. PubMed ID: 34732714
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
14. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
15. CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
Bommi-Reddy A; Park-Chouinard S; Mayhew DN; Terzo E; Hingway A; Steinbaugh MJ; Wilson JE; Sims RJ; Conery AR
PLoS One; 2022; 17(3):e0262378. PubMed ID: 35353838
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
17. Confirmation of EP300 gene mutations as a rare cause of Rubinstein-Taybi syndrome.
Zimmermann N; Acosta AM; Kohlhase J; Bartsch O
Eur J Hum Genet; 2007 Aug; 15(8):837-42. PubMed ID: 17299436
[TBL] [Abstract][Full Text] [Related]
18. Regulation of RB1CC1/FIP200 stability and autophagy function by CREBBP-mediated acetylation in an intrinsically disordered region.
Yi F; Cai C; Ruan B; Hao M; Yeo SK; Haas M; Yang F; Zhang X; Guan JL
Autophagy; 2023 Jun; 19(6):1662-1677. PubMed ID: 36394358
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors.
Crawford MC; Tripu DR; Barritt SA; Jing Y; Gallimore D; Kales SC; Bhanu NV; Xiong Y; Fang Y; Butler KAT; LeClair CA; Coussens NP; Simeonov A; Garcia BA; Dibble CC; Meier JL
bioRxiv; 2023 May; ():. PubMed ID: 37292747
[TBL] [Abstract][Full Text] [Related]
20. Exploitation of EP300 and CREBBP Lysine Acetyltransferases by Cancer.
Attar N; Kurdistani SK
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 27881443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
